CytomX Therapeutics to Present at Upcoming November Investor Conferences

CytomX Therapeutics (CTMX) management will participate in the Guggenheim healthcare investor conference on November 9, 2026, in Boston.

Rhea-AI Summary

CytomX Therapeutics (CTMX) management will participate in the Guggenheim healthcare investor conference on November 9, 2026, in Boston. Its fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference is scheduled for 3:30 p.m. ET.

Management will also attend the Jefferies Global Healthcare Conference in London on November 18, 2026, with a fireside chat at 8:30 a.m. GMT. Live webcasts will be available on CytomX’s Events and Presentations webpage. Management will be available for one-on-one meetings with investors registered to attend the conferences.

Argus 15 min delay 18 alerts

-7.48% vs previous close $2.17 last price 2.6x rel. volume Open Argus

Details

Market move: CTMX -7.48% vs previous close. November investor conferences

$2.14 – $2.45 Day Range

$471.75M Mkt Cap at Last Price

On Nov 2, the day this news came out, the latest delayed price for CTMX is 7.48% below the previous close. Our momentum scanner has recorded 18 alerts for this stock so far that day. The latest delayed price is $2.17. Relative volume is elevated at 2.6x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

antibody-drug conjugates, topoisomerase-1 inhibitor, epcam, interferon alpha-2b

4 terms

antibody-drug conjugates medical

"therapeutic candidates across multiple treatment modalities including antibody-drug conjugates"

A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.

topoisomerase-1 inhibitor medical

"armed with a topoisomerase-1 inhibitor payload"

A topoisomerase-1 inhibitor is a type of drug that blocks an enzyme responsible for untangling DNA so cells can copy and repair it; imagine stopping a person who smooths knots in a rope so the rope can be used. Investors pay attention because these drugs are used to treat cancers and other diseases, so their clinical results, safety profile, regulatory approvals, and patent position directly affect a company’s revenue prospects and stock value.

epcam medical

"directed toward epithelial cell adhesion molecule (EpCAM)"

EpCAM is a protein on the surface of many epithelial cells that is often found at higher levels on certain cancer cells; it helps cells stick together and serves as a visible marker that lab tests and drugs can detect or target. Investors care because diagnostics or therapies that use EpCAM can help identify cancers, deliver treatments directly to tumor cells, or form the basis of clinical trials and partnerships — like a visible flag companies use to find, monitor, or attack tumor cells.

interferon alpha-2b medical

"a masked interferon alpha-2b PROBODY® cytokine"

Interferon alpha-2b is a laboratory-produced version of a natural immune signaling protein used as a medicine to boost the body’s defenses against certain viral infections and some cancers. Think of it as a software update that tells immune cells to act more aggressively; its clinical trial results, regulatory approvals, supply chain and patent position directly affect potential sales, development costs and investment risk in companies that make or sell it.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in November.

Guggenheim 3^rd Annual Healthcare Innovation Conference
Date: Monday, November 9, 2026
Fireside Chat: 3:30 p.m. ET
Location: Boston, MA

Jefferies Global Healthcare Conference in London
Date: Wednesday, November 18, 2026
Fireside Chat: 8:30 a.m. GMT
Location: London, UK

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY^® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY^® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).

Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com

Investor Contact:
Precision AQ
Stephanie Ascher
stephanie.ascher@precisionaq.com

Media Contact:
Precision AQ
Colleen Ketchum
colleen.ketchum@precisionaq.com